BLAIV (INFUSION)INJECTABLE3 Generics Approved
Approved
Jan 2026
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
AVTOZMA (tocilizumab) by Celltrion is interleukin 6 receptor antagonists [moa]. Approved for interleukin-6 receptor antagonist [epc]. First approved in 2026.
Drug data last refreshed 2h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVTOZMA is a monoclonal antibody (mAb) IL-6 receptor antagonist that blocks both soluble and membrane-bound IL-6 receptors to inhibit pro-inflammatory IL-6 signaling. It is indicated across a broad spectrum of inflammatory and autoimmune conditions including rheumatoid arthritis, giant cell arteritis, juvenile idiopathic arthritis, CAR-T-induced cytokine release syndrome, and severe COVID-19 in hospitalized patients. The mechanism targets IL-6, a pleiotropic cytokine central to T-cell activation, immunoglobulin secretion, and acute phase protein synthesis.
Launch
Very recent launch (January 2026) with moderate competitive pressure (30/100); expect expanding team infrastructure and aggressive market penetration activities in the first 24 months.
Mechanism of Action
Interleukin 6 Receptor Antagonists
Pharmacologic Class:
Interleukin-6 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Started Jul 2026
230 enrolled
Multiple Myeloma
Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)
Started Jul 2026
30 enrolled
Relapsed/Refractory Multiple Myeloma (RRMM)
Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis
Started Dec 2025
78 enrolled
Giant Cell Arteritis (GCA)
RCT of Tocilizumab for Anti-MDA5+DM
Started Nov 2025
110 enrolled
Dermatomyositis
Interleukin-6 Guided Treatment With Dexamethasone or Tocilizumab in Patients Hospitalized With Acute Respiratory Symptoms - a Feasibility Study
Started Oct 2025
60 enrolled
Acute Hypoxemic Respiratory Failure
Worked on AVTOZMA at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.